Longbow Capital

MessageBird B.V. specializes in cloud-based software solutions designed for customer communication, including voice services, text messaging, programmable conversations, and notifications. Founded in 2011 and headquartered in Amsterdam, the company operates additional offices in cities such as San Francisco, Singapore, and London. As a unique cloud communications platform with its own telecommunications carrier infrastructure, MessageBird connects over 15,000 enterprises with their global customers through reliable SMS, Voice, and Chat APIs. The company's mission is to modernize customer communication by simplifying complex processes, and it is supported by a diverse team representing over 20 nationalities.

MessageBird B.V. specializes in cloud-based software solutions designed for customer communication, including voice services, text messaging, programmable conversations, and notifications. Founded in 2011 and headquartered in Amsterdam, the company operates additional offices in cities such as San Francisco, Singapore, and London. As a unique cloud communications platform with its own telecommunications carrier infrastructure, MessageBird connects over 15,000 enterprises with their global customers through reliable SMS, Voice, and Chat APIs. The company's mission is to modernize customer communication by simplifying complex processes, and it is supported by a diverse team representing over 20 nationalities.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry. Service division offers technologies designed to clone and express challenging genes to give high-quality recombinant protein displaying functional domains of the target. We also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.

Sky Medical Technology Limited develops innovative neuromuscular electro-stimulation medical devices aimed at enhancing vascular health. Their flagship products include the geko device, which stimulates the common peroneal nerve to activate muscle pumps and improve blood flow, and the firefly device, designed for athletes to enhance lower limb circulation for quicker recovery. The company's OnPulse™ therapy represents a significant advancement in bioelectronic medicine, offering clinically proven solutions for various acute and chronic circulatory conditions, including the prevention of blood clots, treatment of swelling post-surgery, and management of non-healing wounds. These devices are utilized by healthcare professionals, including surgeons, nurses, physiotherapists, and podiatrists, across NHS and private hospitals, as well as in clinical studies. Sky Medical Technology distributes its products globally, reaching markets in Asia, Europe, the Middle East, and North America. Founded in 2006 and based in High Wycombe, United Kingdom, the company addresses the needs of over forty million individuals facing vascular-related health challenges.

Calon Cardio-Technology Ltd develops implantable micro blood pumps for the treatment of chronic heart failure. It offers MiniVAD, a miniature implantable blood pump that is implanted into the left ventricle of the failing heart to help provide blood supply to the body, alleviate the debilitating symptoms of heart failure, and slow or halt heart failure disease progression. The company’s products also comprise MicroVAD, a miniaturized pump for the earlier treatment of patients progressing through the spectrum of advancing heart failure; and CathVAD, a catheter delivered micro-pump for the treatment of acute heart failure.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

Ambicare Health Ltd develops a portfolio of wearable light sources for medical and consumer healthcare applications. The company offers Ambulight PDT, a light-emitting sticking plaster for the treatment of non-melanoma skin cancer. Its light-emitting sticking plasters are used in photodynamic therapy (PDT) which is an alternative to surgery for various forms of skin cancer. The company also offers Lustre Pure Light Classic that delivers blue light therapy to fight spots and acne; and Lustre Pure Light Pro that delivers portable blue light therapy to fight spots and acne. It sells its products through distributors, as well as online. The company was formerly known as Lumicure Ltd and changed its name to Ambicare Health Ltd in August 2009. Ambicare Health Ltd was founded in 2004 and is based in Livingston, United Kingdom.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products. Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling the drug-resistant bacteria that are at the centre of a global healthcare crisis.

Biotronics3D, Ltd., based in London, develops and markets software applications for the diagnostic imaging industry. The company offers a range of innovative products, including the 3Dnet Suite, a multi-purpose medical imaging application for clinical data analysis, and its specialized tools such as 3Dnet Colon for virtual colonoscopy and 3Dnet Vessel for identifying vascular anomalies. The flagship product, 3Dnet Enterprise Suite, has received FDA clearance and is CE marked, underscoring its compliance with regulatory standards. Biotronics3D aims to enhance healthcare by improving the extraction of diagnostic data and making it readily available at the point of care. Established in 2004, the company is certified under EN ISO 13485:2003.

CyDen is a British Health and Beauty company and the leading developer of intense pulsed light (IPL) hair removal devices for use in the home.

Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry. Service division offers technologies designed to clone and express challenging genes to give high-quality recombinant protein displaying functional domains of the target. We also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.